Back to search results

Durysta for Ocular Surface Damage in Glaucoma

This study is looking at how a single injection of Durysta (bimatoprost intracameral implant 10 µg) affects inflammation on the surface of your eye. Researchers want to see if reducing the need for daily eye drops by using Durysta can lower levels of a specific inflammation marker called caspase-1. You might be able to join if you have open-angle glaucoma or are suspected of having it, have had cataract surgery, and use a few daily glaucoma eye drops. The study will measure changes in inflammation over three months after the Durysta injection. The current recruitment status is unclear, and the study plans to enroll 20 participants.

Study design
This is an interventional study planning to enroll 20 participants. All participants will receive a one-time injection of Durysta.
What's involved
You will receive a one-time injection of Durysta and be followed for a total of 3 months. Measurements will be taken at baseline, 1 month, and 3 months post-injection.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 3 months after the Durysta injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07217678

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Recruiting
PHASE4Ages 18+InterventionalTreatment
University of Miami
~20 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:Durysta, Bimatoprost Intracameral Implant 10 µg

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Caspase-1 mRNA Expression Following Durysta Injection
Measured over Baseline, post-injection 1 month, post-injection 3 months

Conditions

Glaucoma
Open-Angle Glaucoma
Ocular Hypertension
Glaucoma Suspect

Explore related trials

Glaucoma suspectOcular HypertensionOpen Angle Glaucoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Swarup S Swaminathan, MD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Javier Paredes, BA, MBA
[email protected]
305-326-6387
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eye with open-angle glaucoma or suspected of open-angle glaucoma
Pseudophakic in eye of interest with Shafer grading ≥3
≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA)
Good adherence to medication regimen - screening questions to be asked of potential subject:
In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%)
When was the last administration? (Last dose must have been within last 24 hours)
Presence of punctate epithelial erosions in the cornea (NEI scale \> 3)

Exclusion

Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion)
Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines)
Use of preservative-free hypotensive medications
Any clinical contraindications to receiving intracameral bimatoprost implantation
History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis)
History of partial or full corneal transplant
History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months
History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months

What this trial measures

  • Change in Caspase-1 mRNA Expression Following Durysta InjectionBaseline, post-injection 1 month, post-injection 3 months

    The primary outcome is evaluating whether the level of caspase-1 from the ocular surface changes after the Durysta injection when the number of topical medications is reduced. Higher values indicate more inflammation, while lower values indicate less information and a more stable ocular surface. The Caspase-1 level will be measured using RT-PCR.